Future ICOS-directed strategies, whether agonistic or antagonistic, monoclonal or bispecific, will require rational combination approaches and biomarker-driven patient selection to fully harness this pathway's therapeutic potential.
First-pass extracted concept
ICOS agonism
Candidate: concept label1 source documents4 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
ICOS-directed strategies
Evidence Snippets
Supporting Sources
Linked Claims
Limited clinical responses with feladilimab echo similar experiences with vopratelimab and other ICOS agonists.
Quoted textsource-backed
clinical responses were limited-echoing similar experiences with vopratelimab (JTX-2011) and other ICOS agonists.
Effective ICOS modulation depends not only on receptor engagement but also on spatial and temporal regulation of effector versus regulatory T-cell responses.
Quoted textsource-backed
These outcomes highlight that effective ICOS modulation depends not only on receptor engagement but also on spatial and temporal regulation of effector versus regulatory T-cell responses.
ICOS is minimally present on naïve T cells and is upregulated following T-cell receptor engagement.
Quoted textsource-backed
Unlike constitutively expressed co-stimulatory molecules, ICOS is minimally present on naïve T cells and is upregulated following T-cell receptor engagement.
Future ICOS-directed strategies will require rational combination approaches and biomarker-driven patient selection.
Quoted textsource-backed
Future ICOS-directed strategies, whether agonistic or antagonistic, monoclonal or bispecific, will require rational combination approaches and biomarker-driven patient selection